Effect of rituximab on reducing the panel-reactive antibody in dialysis patients of transplant candidate

IF 0.2 Q4 UROLOGY & NEPHROLOGY

Journal of Renal Injury Prevention Pub Date : 2022-01-17 DOI:10.34172/jrip.2022.31928

A. Aref, Samaneh Tirom, H. Shahbazian, A. Ghorbani

{"title":"Effect of rituximab on reducing the panel-reactive antibody in dialysis patients of transplant candidate","authors":"A. Aref, Samaneh Tirom, H. Shahbazian, A. Ghorbani","doi":"10.34172/jrip.2022.31928","DOIUrl":null,"url":null,"abstract":"Introduction: Based on the evidence, rituximab may be an effective treatment for kidney transplantation for reducing panel-reactive antibody. Objectives: This study was conducted to investigate the effect of rituximab on reducing the panel in transplant dialysis patients. Patients and Methods: This is an interventional study that was conducted on 20 dialysis patients who were candidates for kidney transplantation. Patients first had a panel-reactive antibody test and patients with a panel-reactive antibody above the age of 30 were included in the study. First, rituximab was administered at a dose of one gram and then after two weeks, another dose of one gram was administered. Panel-reactive antibody was measured baseline, one and six months later. Results: One and six months after stopping the drug, we found a significant decrease in the mean amount of reactive antibodies. Additionally, six months after stopping the drug, a significant decrease in the level of patients’ reactive antibodies in comparison to one month before taking the drug was detected (P<0.05). Conclusion: The findings showed that treatment with rituximab is useful for reducing panel-reactive antibody in kidney transplant patients. However, more studies are needed to optimize rituximab injection protocols.","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":" ","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2022-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Renal Injury Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/jrip.2022.31928","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Based on the evidence, rituximab may be an effective treatment for kidney transplantation for reducing panel-reactive antibody. Objectives: This study was conducted to investigate the effect of rituximab on reducing the panel in transplant dialysis patients. Patients and Methods: This is an interventional study that was conducted on 20 dialysis patients who were candidates for kidney transplantation. Patients first had a panel-reactive antibody test and patients with a panel-reactive antibody above the age of 30 were included in the study. First, rituximab was administered at a dose of one gram and then after two weeks, another dose of one gram was administered. Panel-reactive antibody was measured baseline, one and six months later. Results: One and six months after stopping the drug, we found a significant decrease in the mean amount of reactive antibodies. Additionally, six months after stopping the drug, a significant decrease in the level of patients’ reactive antibodies in comparison to one month before taking the drug was detected (P<0.05). Conclusion: The findings showed that treatment with rituximab is useful for reducing panel-reactive antibody in kidney transplant patients. However, more studies are needed to optimize rituximab injection protocols.

查看原文本刊更多论文

利妥昔单抗降低移植候选透析患者群体反应性抗体的作用

引言：根据证据，利妥昔单抗可能是减少群体反应性抗体的一种有效的肾移植治疗方法。目的：本研究旨在探讨利妥昔单抗在移植透析患者中减少面板的作用。患者和方法：这是一项对20名肾移植候选透析患者进行的介入性研究。患者首先进行了群体反应性抗体测试，30岁以上群体反应性的患者被纳入研究。首先，利妥昔单抗的剂量为1克，两周后，再给药1克。在基线、一个月和六个月后测量面板反应性抗体。结果：停药一个月和六个月后，我们发现反应性抗体的平均数量显著减少。此外，停药6个月后，患者的反应性抗体水平与服药前1个月相比显著下降（P<0.05）。结论：利妥昔单抗治疗有助于降低肾移植患者的群体反应性抗体。然而，还需要更多的研究来优化利妥昔单抗的注射方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Renal Injury Prevention UROLOGY & NEPHROLOGY-

CiteScore

1.60

自引率

0.00%

发文量

期刊介绍： The Journal of Renal Injury Prevention (JRIP) is a quarterly peer-reviewed international journal devoted to the promotion of early diagnosis and prevention of renal diseases. It publishes in March, June, September and December of each year. It has pursued this aim through publishing editorials, original research articles, reviews, mini-reviews, commentaries, letters to the editor, hypothesis, case reports, epidemiology and prevention, news and views and renal biopsy teaching point. In this journal, particular emphasis is given to research, both experimental and clinical, aimed at protection/prevention of renal failure and modalities in the treatment of diabetic nephropathy. A further aim of this journal is to emphasize and strengthen the link between renal pathologists/nephropathologists and nephrologists. In addition, JRIP welcomes basic biomedical as well as pharmaceutical scientific research applied to clinical nephrology. Futuristic conceptual hypothesis that integrate various fields of acute kidney injury and renal tubular cell protection are encouraged to be submitted.